Compare SSB & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSB | CYTK |
|---|---|---|
| Founded | 1933 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 10.7B |
| IPO Year | 2008 | 2004 |
| Metric | SSB | CYTK |
|---|---|---|
| Price | $106.12 | $80.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | ★ $118.00 | $89.26 |
| AVG Volume (30 Days) | 782.1K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 12.91 | N/A |
| EPS | ★ 2.28 | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $10.07 | $7.37 |
| Revenue Next Year | $6.51 | $310.19 |
| P/E Ratio | $44.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $84.48 | $32.89 |
| 52 Week High | $108.46 | $88.31 |
| Indicator | SSB | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 67.49 | 50.24 |
| Support Level | $92.40 | $59.07 |
| Resistance Level | $108.46 | $88.31 |
| Average True Range (ATR) | 1.80 | 2.99 |
| MACD | 0.20 | -0.66 |
| Stochastic Oscillator | 90.38 | 26.60 |
SouthState Bank Corp is a United States-based bank holding company. It provides a wide range of services and products to its customers through a wholly-owned bank subsidiary. The Bank provides retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans through financial centers in Alabama, Florida, Georgia, North Carolina, South Carolina, and Virginia. These services include demand, time, and savings deposits, lending and credit card servicing, ATM processing, and wealth management and trust services.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.